Avadel Pharmaceuticals plc - Ordinary Share (AVDL) earnings
AVDL earnings moved a median of -0.43% by the close. Quarterly and annual AVDL reports and results, each read against the price at its own news timestamp. Back to the AVDL overview →
21 measured AVDL earnings events.
Where these AVDL earnings landedvs 21 measured AVDL earnings reactions
| Middle 50% of AVDL earnings reactions | -3.21% to +1.26% |
|---|---|
| Median reaction (to close) | -0.43% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 AVDL earnings events with a measured close landed between -3.21% and +1.26%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.27% | +0.32% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +0.27% | +0.32% | |
| Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance | Press release | -11.32% | -9.00% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -11.32% | -9.00% | |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 | Press release | +0.42% | -1.31% | |
| Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance | Press release | -3.03% | -2.87% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -3.03% | -2.87% | |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7 | Press release | +1.23% | +3.98% | |
| Form 10-K AVADEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +3.97% | -3.21% | |
| Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Press release | -1.72% | -12.97% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -1.82% | -11.45% | |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 | Press release | -3.32% | -1.33% | |
| Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Press release | -8.04% | -8.96% | |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8 | Press release | +0.36% | +0.24% | |
| Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | +3.84% | +2.27% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +3.84% | +2.27% | |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 | Press release | +0.76% | -0.43% | |
| Form 10-K/A AVADEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.61% | +0.22% | |
| Form 10-K AVADEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +1.76% | +7.27% | |
| Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | +4.62% | +1.26% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +4.62% | +1.26% |
Keep exploring
More AVDL: analyst actions → · SEC filings → · AVDL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Cumberland Pharmaceuticals Inc. (CPIX) | 245 | 0.00% | 49% |
| electroCore, Inc. (ECOR) | 245 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.